// App-Quantinova.ai

: Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD)

Researchers

Presenter

  • Oscar Henry Mayer

Principal Investigators

  • Mika Leinonen

  • Laurent Servais

  • Chiara Straathof

  • Ulrike Schara

  • Thomas Voit

  • Eugenio Mercuri

Medical Centers

  • Children's Hospital of Philadelphia, Philadelphia, United States of America

  • Santhera Pharmaceuicals, Pratteln, Switzerland

  • Centre de Référence Neuromusculaire, CHU Liège, Liege, Belgium

  • Leiden University Medical Centre, Leiden, Netherlands

  • Universitäts-Klinikum Essen, Zentrum für Kinderheilikunde/ Sozialpädiatrisches Zentrum, Essen, Germany

  • UCL Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom

  • Pediatric Neurology Unit, Catholic University, Rome, Italy

Locations

  • United States

  • Switzerland

  • Belgium

  • Netherlands

  • Germany

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Duchenne muscular dystrophy

Biomarkers

  • N/A

Drug/Treatment

  • Idebenone

  • Roxithromycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved